Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues
Open accessAbstract
BACKGROUND: Pancreatic adenocarcinoma is one of the cancers with the worst prognosis. The current treatment paradigm based on combination chemotherapy has improved survival over the last decade, but the disease is still fatal in most cases. New therapies exploiting the increasing understanding of the molecular pathology of the disease are needed. Although the disease presents with few recurrent molecular alterations, these represent opportunities for targeted treatments to be developed. However, a minority of cases are devoid of these common alterations. A description of the molecular landscape of this sub-set of pancreatic adenocarcinoma could uncover other molecular lesions present in them that could serve as therapeutic targets. METHODS: The sub-set of pancreatic cancers without the common alterations in KRAS, TP53, CDKN2A and SMAD4 has been examined from published and publicly available pancreatic cancer cohorts for determination of their clinical and molecular characteristics. The cBioportal platform was used for this evaluation and the OncoKB knowledgebase was used for determination of the functional significance of discovered mutations. RESULTS: About 5% to 10% of pancreatic adenocarcinomas present without the usual molecular alterations that characterize the disease. These cases tend to be genomically stable and have low prevalence of microsatellite or chromosome instability. Molecular alterations that are observed in pancreatic cancers in lower frequencies than the four most prevalent alterations, such as DNA Damage Response and epigenetic modifier mutations, are still observed in the sub-set without the common alterations and may be pathogenically relevant. CONCLUSIONS: Despite the absence of most frequent pancreatic cancer alterations in a sub-set of pancreatic adenocarcinomas, this sub-set possesses other alterations in frequencies similar to the rest of pancreatic cancers. Putative targeting of alterations present is discussed and can serve as the basis for targeted therapies development.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Tumors with unique molecular profiles lacking common mutations demonstrate improved overall survival.
“Those tumors with unique molecular profiles lacking common mutations demonstrate improved overall survival, suggesting therapeutic relevance [28].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [28]
5-10% of pancreatic cancers lack common mutations (KRAS, TP53, SMAD4, CDKN2A, CDKN2B) and exhibit diverse mutations, including therapeutic target alterations.
“However, 5–10% of pancreatic cancers lack common mutations (KRAS, TP53, SMAD4, CDKN2A, CDKN2B), exhibiting diverse mutations, including therapeutic target alterations.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [28]
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · see citing works
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · see citing works
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179 · see citing works
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · see citing works
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · see citing works
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969 · see citing works
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T. P., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J. L., & Siegel, R. L. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,690 · see citing works
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · see citing works
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. M., Beroukhim, R., & Getz, G. A. (2011) · Genome biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,469 · see citing works
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · see citing works
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · see citing works
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874 · see citing works
OncoKB: A Precision Oncology Knowledge Base
Chakravarty, D., Gao, J., Phillips, S. M., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R. D., Soumerai, T. E., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,735 · see citing works
Global Burden of 5 Major Types of Gastrointestinal Cancer
Arnold, M., Abnet, C. C., Neale, R. E., Vignat, J., Giovannucci, E. L., McGlynn, K. A., & Bray, F. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.068 · Cited by 2,027 · see citing works
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T. I., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,003 · see citing works
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967 · see citing works
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964 · see citing works
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
Blackford, A. N., & Jackson, S. P. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.05.015 · Cited by 1,953 · see citing works
Genomic and Functional Approaches to Understanding Cancer Aneuploidy
Taylor, A. M., Shih, J., Ha, G., Gao, G. F., Zhang, X., Berger, A. C., Schumacher, S. E., Wang, C., Hu, H., Liu, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.007 · Cited by 1,027 · see citing works
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I.-M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0849 · Cited by 522 · see citing works
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
Golan, T., Kanji, Z. S., Epelbaum, R., Devaud, N., Dagan, E., Holter, S., Aderka, D., Paluch–Shimon, S., Kaufman, B., Gershoni‐Baruch, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.418 · Cited by 437 · see citing works
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Vaccaro, V., Sperduti, I., & Milella, M. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1107627 · Cited by 427 · see citing works
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360 · see citing works
Luchini, C., Brosens, L. A. A., Wood, L. D., Chatterjee, D., Shin, J. I., Sciammarella, C., Fiadone, G., Malleo, G., Salvia, R., Kryklyva, V., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320726 · Cited by 257 · see citing works
Lowery, M. A., Jordan, E., Baştürk, O., Ptashkin, R. N., Zehir, A., Berger, M. F., Leach, T., Herbst, B. T., Askan, G., Maynard, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0899 · Cited by 212 · see citing works
Tan, M. C. B., Baştürk, O., Brannon, R., Bhanot, U. K., Scott, S. N., Bouvier, N., LaFemina, J., Jarnagin, W. R., Berger, M. F., Klimstra, D. S., et al. (2015) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2014.11.029 · Cited by 202 · see citing works
Philip, P. A., Azar, I., Xiu, J., Hall, M. J., Hendifar, A. E., Lou, E., Hwang, J. J., Gong, J., Feldman, R., Ellis, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3581 · Cited by 191 · see citing works
Omori, Y., Ono, Y., Tanino, M. A., Karasaki, H., Yamaguchi, H., Furukawa, T., Enomoto, K., Ueda, J., Sumi, A., Katayama, J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.10.029 · Cited by 189 · see citing works
Lloyd, R. L., Wijnhoven, P. W. G., Ramos‐Montoya, A., Wilson, Z., Illuzzi, G., Falenta, K., Jones, G. N., James, N. H., Chabbert, C. D., Stott, J., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1328-y · Cited by 181 · see citing works
p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells
Bailey, J. M., Hendley, A. M., Lafaro, K. J., Pruski, M. A., Jones, N. C., Alsina, J., Younes, M., Maitra, A., McAllister, F., Iacobuzio-Donahue, C. A., et al. (2016) · Oncogene · doi:10.1038/onc.2015.441 · Cited by 154 · see citing works
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Bannoura, S. F., Khan, H. Y., & Azmi, A. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1013902 · Cited by 118 · see citing works
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
Jette, N., Kumar, M., Radhamani, S., Arthur, G., Goutam, S., Yip, S., Kolinsky, M. P., Williams, G. J., Bose, P., & Lees‐Miller, S. P. (2020) · Cancers · doi:10.3390/cancers12030687 · Cited by 108 · see citing works
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer
Jones, M. R., Lim, H. J., Shen, Y., Pleasance, E., Ch’ng, C., Reisle, C., Leelakumari, S., Zhao, C., Yip, S. S. F., Ho, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx523 · Cited by 108 · see citing works
Kimura, Y., Fukuda, A., Ogawa, S., Maruno, T., Takada, Y., Tsuda, M., Hiramatsu, Y., Araki, O., Nagao, M., Yoshikawa, T., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.039 · Cited by 90 · see citing works
Hosoda, W., Sasaki, E., Murakami, Y., Yamao, K., Shimizu, Y., & Yatabe, Y. (2015) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-015-1751-6 · Cited by 88 · see citing works
Golan, T., Barenboim, A., Lahat, G., Nachmany, I., Goykhman, Y., Shacham‐Shmueli, E., Halpern, N., Brazowski, E., Geva, R., Wolf, I., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08469-8 · Cited by 81 · see citing works
Gout, J., Perkhofer, L., Morawe, M., Arnold, F., Ihle, M., Biber, S., Lange, S., Roger, É., Kraus, J. M., Stifter, K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319970 · Cited by 81 · see citing works
Mutations of p53 associated with pancreatic cancer and therapeutic implications
Voutsadakis, I. A. (2021) · Annals of Hepato-Biliary-Pancreatic Surgery · doi:10.14701/ahbps.2021.25.3.315 · Cited by 75 · see citing works
Self-citationWang, W., Friedland, S. C., Guo, B., O'Dell, M. R., Alexander, W. B., Whitney-Miller, C. L., Agostini-Vulaj, D., Huber, A. R., Myers, J. R., Ashton, J., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315541 · Cited by 70 · see citing works
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
Botta, G. P., Kato, S., Patel, H., Fanta, P. T., Lee, S., Okamura, R., & Kurzrock, R. (2021) · JCI Insight · doi:10.1172/jci.insight.150453 · Cited by 70 · see citing works
Tomihara, H., Carbone, F., Perelli, L., Huang, J. K.-L., Soeung, M., Rose, J. L., Robinson, F. S., Lissanu, Y., Feng, N., Takeda, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3922 · Cited by 57 · see citing works
Thibodeau, S., & Voutsadakis, I. A. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7010007 · Cited by 54 · see citing works
Self-citationMas, L., Lupinacci, R. M., Cros, J. F., Bachet, J., Coulet, F., & Svrcek, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136756 · Cited by 43 · see citing works
Schaefer, E. J., Wang, H. C., Karp, H. Q., Meyer, C. A., Cejas, P., Gearhart, M. D., Adelman, E. R., Fares, I., Apffel, A. M., Lim, K., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0115 · Cited by 42 · see citing works
Thompson, E. D., Roberts, N. J., Wood, L. D., Eshleman, J. R., Goggins, M., Kern, S. E., Klein, A. P., & Hruban, R. H. (2020) · Modern Pathology · doi:10.1038/s41379-020-0629-6 · Cited by 39 · see citing works
Kawabata, H., Ono, Y., Tamamura, N., Oyama, K., Ueda, J., Sato, H., Takahashi, K., Taniue, K., Okada, T., Fujibayashi, S., et al. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-021-01846-4 · Cited by 28 · see citing works
Oncogenic NRG1 Fusions: A New Hope for Targeted Therapy in Pancreatic Cancer
Aguirre, A. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1280 · Cited by 27 · see citing works
Roger, E., Gout, J., Arnold, F., Beutel, A., Müller, M., Abaei, A., Barth, T., Rasche, V., Seufferlein, T., Perkhofer, L., et al. (2020) · Cells · doi:10.3390/cells9092110 · Cited by 26 · see citing works
Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities
Zhang, C., Mei, W., & Zeng, C. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188707 · Cited by 26 · see citing works
Xu, S., Guo, Y. L., Zeng, Y., Song, Z., Zhu, X., Fan, N., Zhang, Z., Ren, G., Zang, Y., & Rao, W. (2021) · BMC Cancer · doi:10.1186/s12885-021-07792-x · Cited by 19 · see citing works
Pancreatic ductal adenocarcinoma in the era of precision medicine
Zheng-Lin, B., & O'Reilly, E. M. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.01.005 · Cited by 16 · see citing works
Liu, D., Benzaquen, J., Morris, L. G. T., Ilié, M., & Hofman, P. M. (2022) · Cancers · doi:10.3390/cancers14112816 · Cited by 15 · see citing works
Future directions in drug development in pancreatic cancer
Lambert, A., Conroy, T., & Ducreux, M. P. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.002 · Cited by 14 · see citing works
The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer
Umemoto, K., & Sunakawa, Y. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103465 · Cited by 12 · see citing works
Arid1a: A Gatekeeper in the Development of Pancreatic Cancer From a Rare Precursor Lesion
Liu, M. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.05.046 · Cited by 7 · see citing works
Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation
Zhao, X., Zhou, J., Dong, L., Zhang, H., & Ye, Y. (2019) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000550 · Cited by 6 · see citing works
Neoadjuvant treatment of localized pancreatic adenocarcinoma
Leal, A. D., Messersmith, W. A., & Lieu, C. H. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-250 · Cited by 4 · see citing works
Flagged first, then by citations
3 of the 60 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Yu, B., Shao, S., & Ma, W. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217350 · Cited by 112 · see citing works
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110 · see citing works
Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications
Avcı, Ç. B., Bağca, B. G., Nikanfar, M., Takanlou, L. S., Takanlou, M. S., & Nourazarian, A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1442888 · Cited by 94 · see citing works
Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
Kumar, P. A., Serinelli, S., Zaccarini, D. J., Huang, R. S. P., Danziger, N. A., Janovitz, T., Basnet, A., Sivapiragasam, A., Graziano, S. L., & Ross, J. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1169586 · Cited by 12 · see citing works
Shenoy, A., Yousif, A., & Hussain, M. D. (2025) · Cancers · doi:10.3390/cancers17081319 · Cited by 10 · see citing works
Decoding pancreatic cancer: key risk factors across genetics and lifestyle
Sharma, R., Ghosh, R., Kumar, S., Komal, K., & Kumar, M. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2464563 · Cited by 9 · see citing works
Comprehensive Genomic Studies on the Cell Blocks of Pancreatic Cancer
da Silva, R. S., Pina, M. J., Cirnes, L., Gouveia, L. B., Albergaria, A., & Schmitt, F. C. (2024) · Diagnostics · doi:10.3390/diagnostics14090906 · Cited by 7 · see citing works
Zhang, J., Zhang, X., Wu, R., & Dong, C.-S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1569088 · Cited by 6 · see citing works
Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward
Voutsadakis, I. A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47060454 · Cited by 5 · see citing works
Self-citationTavano, F., Latiano, A., Palmieri, O., Gioffreda, D., Latiano, T. P., Gentile, A., Tardio, M., Latiano, T. P., Gentile, M., Terracciano, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158436 · Cited by 4 · see citing works
Sunildutt, N., Ahmed, F., Salih, A. R. C., Kim, H. C., & Choi, K. H. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109481 · Cited by 3 · see citing works
Kuznetsova, O. A., Федянин, М. Ю., Ivanov, M. V., Трякин, А. А., Borshchev, G. G., Lebedeva, A., Михайлович, В. Е., Витальевич, Л. Е., Shamrikova, V., Stepanova, M., et al. (2023) · Malignant tumours · doi:10.18027/2224-5057-2023-13-3s1-7-17 · Cited by 1 · see citing works
Yuan, Z., Zhiwei, Y. U., Xu, Q., Huang, D., & Cui, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1791707
Li, R., Xu, X., Zhang, W., & Zhan, Y.-Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1843505
Genetics of Pancreatic Cystic Tumors
Sharma, R. K., Singh, A., Rana, S. S., & Mishra, N. K. (2026) · Springer eBooks · doi:10.1007/978-981-92-0654-4_13
- Authors
- Voutsadakis, I. A., & Digklia, A.
- Affiliations
- Sault Area Hospital (CA)
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Voutsadakis, Ioannis A.
- Venue
- Chinese Clinical Oncology
- Publisher
- AME Publishing Company
- Published
- 2023-02
- Volume
- 12
- Issue
- 1
- Pages
- 2-2
- ISSN
- 2304-3865 (ISSN-L)
- 2304-3873
- OpenAlex
- W4320481574
- Cited by
- 16
- References
- 60
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 6 · 2023: 3
- FWCI
- 0.52
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Chinese Clinical Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (acceptedVersion, cc-by-nc-nd)
- IRIS (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pancreatic ductal adenocarcinoma, KRAS wild-type, wild-type p53, genomic landscape, microsatellite instability, chromosomal instability, targeted therapy, molecular alterations
- MeSH terms
- Adenocarcinoma, Humans, Mutation, Pancreatic Neoplasms, Biomarkers, Tumor, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Genomics, Smad4 Protein, DNA Copy Number Variations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
